FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with metastatic colorectal cancer whose tumors have alterations that affect DNA repair. In the phase 2 trial that led to the accelerated approval, 28% of patients treated with nivolumab experienced an objective response.
Results of an early-phase trial showed that a treatment vaccine personalized to a specific patient’s cancer generated a robust immune response against the cancer and may have helped to prevent it from returning.
This recently published page discusses the role of the NIH Clinical Center in cancer research. NCI researchers conduct numerous clinical trials at NIH’s research hospital in Bethesda, Maryland, every year to improve cancer treatment, screening, and diagnosis.
This phase 2 trial studies the side effects and how well pembrolizumab, capecitabine, and oxaliplatin work in treating patients with biliary tract cancer that has spread to other places in the body and cannot be removed by surgery.
This phase 2 trial studies how well fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) works in imaging patients with prostate cancer that is high risk or has returned after a period of improvement. Fluorine F 18 DCFPyL is a radioactive tracer compound that targets the prostate-specific membrane antigen.
This phase 2 trial will assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL patients treated with PT2385.
